Literature DB >> 19756300

Receptor tyrosine kinase signaling: a view from quantitative proteomics.

Joern Dengjel1, Irina Kratchmarova, Blagoy Blagoev.   

Abstract

Growth factor receptor signaling via receptor tyrosine kinases (RTKs) is one of the basic cellular communication principals found in all metazoans. Extracellular signals are transferred via membrane spanning receptors into the cytoplasm, reversible tyrosine phosphorylation being the hallmark of all RTKs. In recent years proteomic approaches have yielded detailed descriptions of cellular signaling events. Quantitative proteomics is able to characterize the exact position and strength of post-translational modifications (PTMs) providing essential information for understanding the molecular basis of signal transduction. Numerous new post-translational modification sites have been identified by quantitative mass spectrometry-based proteomics. In addition, plentiful new players in signal transduction have been identified underlining the complexity and the modular architecture of most signaling networks. In this review, we outline the principles of signal transduction via RTKs and highlight some of the new insights obtained from proteomic approaches such as protein microarrays and quantitative mass spectrometry.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19756300     DOI: 10.1039/b909534a

Source DB:  PubMed          Journal:  Mol Biosyst        ISSN: 1742-2051


  18 in total

1.  Dynamics of the skeletal muscle secretome during myoblast differentiation.

Authors:  Jeanette Henningsen; Kristoffer T G Rigbolt; Blagoy Blagoev; Bente Klarlund Pedersen; Irina Kratchmarova
Journal:  Mol Cell Proteomics       Date:  2010-07-14       Impact factor: 5.911

Review 2.  Decoding signalling networks by mass spectrometry-based proteomics.

Authors:  Chunaram Choudhary; Matthias Mann
Journal:  Nat Rev Mol Cell Biol       Date:  2010-05-12       Impact factor: 94.444

Review 3.  Functional proteomics to dissect tyrosine kinase signalling pathways in cancer.

Authors:  Walter Kolch; Andrew Pitt
Journal:  Nat Rev Cancer       Date:  2010-08-19       Impact factor: 60.716

4.  From the black widow spider to human behavior: Latrophilins, a relatively unknown class of G protein-coupled receptors, are implicated in psychiatric disorders.

Authors:  Ariel F Martinez; Maximilian Muenke; Mauricio Arcos-Burgos
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-11-12       Impact factor: 3.568

5.  GProX, a user-friendly platform for bioinformatics analysis and visualization of quantitative proteomics data.

Authors:  Kristoffer T G Rigbolt; Jens T Vanselow; Blagoy Blagoev
Journal:  Mol Cell Proteomics       Date:  2011-05-20       Impact factor: 5.911

Review 6.  Mass spectrometry accelerates membrane protein analysis.

Authors:  Jeffrey N Savas; Benjamin D Stein; Christine C Wu; John R Yates
Journal:  Trends Biochem Sci       Date:  2011-05-26       Impact factor: 13.807

7.  Phosphoproteomic studies of receptor tyrosine kinases: future perspectives.

Authors:  Paul H Huang
Journal:  Mol Biosyst       Date:  2011-12-02

8.  Development of a 5-plex SILAC method tuned for the quantitation of tyrosine phosphorylation dynamics.

Authors:  Manuel Tzouros; Sabrina Golling; David Avila; Jens Lamerz; Marco Berrera; Martin Ebeling; Hanno Langen; Angélique Augustin
Journal:  Mol Cell Proteomics       Date:  2013-07-23       Impact factor: 5.911

9.  Phosphoproteomics-based modeling defines the regulatory mechanism underlying aberrant EGFR signaling.

Authors:  Shinya Tasaki; Masao Nagasaki; Hiroko Kozuka-Hata; Kentaro Semba; Noriko Gotoh; Seisuke Hattori; Jun-ichiro Inoue; Tadashi Yamamoto; Satoru Miyano; Sumio Sugano; Masaaki Oyama
Journal:  PLoS One       Date:  2010-11-10       Impact factor: 3.240

10.  The immunopharmacologic potential of Semaxanib and new generation directed therapeutic drugs: Receptor tyrosine kinase regulation with anti-tumorigenensis/angiogenesis properties.

Authors:  John J Haddad
Journal:  Saudi Pharm J       Date:  2011-09-23       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.